(Q44728230)

5 December 2017

title

Topical imiquimod immunotherapy in the management of lentigo maligna (English)

1 reference

5 December 2017

1 reference

A M Powell

1

1 reference

5 December 2017

R Russell-Jones

series ordinal

2

1 reference

5 December 2017

R J Barlow

series ordinal

3

1 reference

5 December 2017

language of work or name

1 reference

1 January 2004

1 reference

Clinical and Experimental Dermatology

5 December 2017

published in

1 reference

5 December 2017

volume

29

1 reference

5 December 2017

issue

1

1 reference

5 December 2017

page(s)

15-21

1 reference

Mohs' micrographic surgery using frozen sections alone may be unsuitable for detecting single atypical melanocytes at the margins of melanoma in situ

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Survey of U.K. current practice in the treatment of lentigo maligna.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Immunomodulatory and pharmacologic properties of imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Extensive lentigo maligna clearing with topical imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Topical imiquimod in the treatment of metastatic melanoma to skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

U.K. guidelines for the management of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

Imiquimod: a novel treatment for lentigo maligna

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01452.X

10.1111/J.1365-2230.2004.01452.X

21 January 2018

Identifiers

DOI

1 reference

release_jz3qgovzcrebzomw2nqzcoxoze

5 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jz3qgovzcrebzomw2nqzcoxoze

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference